JP Morgan Maintains Neutral on Cardlytics, Raises Price Target to $9
Portfolio Pulse from richadhand@benzinga.com
JP Morgan analyst Doug Anmuth maintains a Neutral rating on Cardlytics (NASDAQ:CDLX) and raises the price target from $6 to $9.
August 04, 2023 | 11:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan maintains a Neutral rating on Cardlytics and raises the price target from $6 to $9.
The raised price target by JP Morgan indicates a positive outlook for Cardlytics. However, the Neutral rating suggests that the stock is expected to perform in line with the market or sector in the next 6-12 months. This could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100